The quality of Tristel's (TSTL) infection control products means that almost all hospitals in its home UK market now use them and so, in order to expand, the group is looking to broaden its horizons.
IC TIP:
Buy
at
139p
The first target is Australia which, according to management, suffers the same problems as the UK does when it comes to hospital-acquired infection and this makes it an ideal market. Tristel has sold its disinfection wipes down under since 2011 and this week was granted regulatory approval for its surface disinfection suite. In the UK these products generated revenue of about £1.2m in the 2016 financial year so therefore Tristel has the opportunity to almost double current sales in Australia.
